Standardized Xeno- And Serum-Free Culture Platform Enables Large-Scale Expansion Of High-Quality Mesenchymal Stem/Stromal Cells From Perinatal And Adult Tissue Sources

Background aims: Mesenchymal stem/stromal cells (MSCs) are of interest for the treatment of graft-versus host disease, autoimmune diseases, osteoarthritis and neurological and cardiovascular diseases. Increasing numbers of clinical trials emphasize the need for standardized manufacturing of these cells. However, many challenges related to diverse isolation and expansion protocols and differences in cell tissue sources exist. As a result, the cell products used in numerous trials vary greatly in characteristics and potency.Methods: The authors have established a standardized culture platform using xenoand serum-free commercial media for expansion of MSCs derived from umbilical cord (UC), bone marrow and adipose-derived (AD) and examined their functional characteristics.Results: MSCs from the tested sources stably expanded in vitro and retained their biomarker expression and normal karyotype at early and later passages and after cryopreservation. MSCs were capable of colony formation and successfully differentiated into osteogenic, adipogenic and chondrogenic lineages. Pilot expansion of UC-MSCs and AD-MSCs to clinical scale revealed that the cells met the required quality standard for therapeutic applications.Conclusions: The authors' data suggest that xenoand serum-free culture conditions are suitable for largescale expansion and enable comparative study of MSCs of different origins. This is of importance for therapeutic purposes, especially because of the numerous variations in pre-clinical and clinical protocols for MSC based products. (C) 2020 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.